Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × Waldenstrom Macroglobulinemia × obinutuzumab × Clear all

Phase

Status

Unknown 1 Recruiting 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, Follicular 2 Waldenstrom Macroglobulinemia 1 Recurrence 1 Lymphoma, B-Cell 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Indolent Non-Hodgkin Lymphoma 1

Interventions

ibrutinib 2 Rituximab 2 Peripheral Blood Stem Cell Transplantation 2 Filgrastim 2 Cyclophosphamide 2 zanubrutinib 1 sargramostim 1 obinutuzumab 1 motesanib diphosphate 1 ledipasvir, sofosbuvir drug combination 1 ibritumomab tiuxetan 1 fludarabine phosphate 1 alethine 1 XELOX 1 Valproic Acid 1 Thalidomide 1 Radiotherapy 1 Psychiatric Rehabilitation 1 Pharmacogenomic Testing 1 Melphalan 1 Leukapheresis 1 Ketamine 1 Interferon-alpha 1 Indium 1 Ifosfamide 1 Gemcitabine 1 Etoposide 1 Dexamethasone 1 Cytarabine 1 Cisplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03679455 2018-11-13

OBI-1

Polish Myeloma Consortium

Phase 2 Unknown

Waldenstrom Macroglobulinemia

Data powered by HemOnc (CC BY 4.0) Colophon ⚡